A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.150.150
Abstract: Proteasome inhibitors (PIs) capitalize on the constitutive activation of NF-KB in AML cells and increase chemosensitivity to anthracyclines and cytarabine. We combined the second generation PI, ixazomib, with the AML salvage regimen MEC (mitoxantrone, etoposide,… read more here.
Keywords: response; membership entity9s; resistant pts; board ... See more keywords
Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1622.1622
Abstract: Introduction: Multiple studies have demonstrated that 40-50% of patients can maintain a treatment free remission (TFR) after having achieved a deep and sustained response to tyrosine kinase inhibitors (TKI) for the treatment of CML. However,… read more here.
Keywords: board directors; membership entity9s; entity9s board; directors advisory ... See more keywords
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1887.1887
Abstract: Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through immune cell engagement and direct tumor targeting. We previously presented data from the dose-escalation cohort, and the… read more here.
Keywords: membership entity9s; funding; entity9s board; research funding ... See more keywords
Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2017.2017
Abstract: Introduction: In September 2013, the Spanish Myeloma Group (PETHEMA/GEM) activated a randomized phase III trial of induction therapy with VRD-GEM for 6 cycles (with extended full dose of lenalidomide from days 1 to 21), followed… read more here.
Keywords: board directors; advisory committees; membership entity9s; entity9s board ... See more keywords
Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2585.2585
Abstract: Introduction: The PIM serine/threonine kinases (PIM1, PIM2 and PIM3) integrate multiple signaling networks and phosphorylate downstream substrates important for cell survival and proliferation (Abstract 5397, AACR 2015). Whereas the PIM kinase isozymes are differentially expressed… read more here.
Keywords: board directors; advisory committees; membership entity9s; entity9s board ... See more keywords
Prognostic Impact of Tandem Autologous Stem Cell Transplantation (ASCT) in Different Response Subgroups after 1st ASCT
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3295.3295
Abstract: Background High dose (HD) chemotherapy with melphalan and autologous stem cell transplantation (ASCT) have been considered a standard treatment for newly diagnosed multiple myeloma (MM) patients for more than 30 years. Two-course (tandem) ASCT proved… read more here.
Keywords: board directors; response; membership entity9s; entity9s board ... See more keywords
Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.413.413
Abstract: Introduction. In follicular lymphoma (FL), no prognostic index has been built based on a cohort of patients treated only with initial immunochemotherapy. Given the emergence of new biomolecular and metabolic prognostic factors in FL, an… read more here.
Keywords: entity9s board; honoraria; consultancy honoraria; membership entity9s ... See more keywords
First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.4748.4748
Abstract: Introduction: Folate deficiency has been widely reported in association with several physiologic and pathologic conditions such as pregnancy, malnutrition, chronic hemolysis, inflammatory bowel disease, alcoholism, and cancer, as well as in conjunction with the administration… read more here.
Keywords: board directors; membership entity9s; entity9s board; directors advisory ... See more keywords
In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.819.819
Abstract: Introduction: Current therapies for relapsed/refractory (rel/ref) T-cell lymphomas (TCLs) induce responses in only 25-30% of patients (pts). Phosphoinositide-3-kinases (PI3K) play a pivotal role in cell signaling and PI3K isoforms have distinct roles in the development,… read more here.
Keywords: research; membership entity9s; entity9s board; research funding ... See more keywords